JP2003513012A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003513012A5 JP2003513012A5 JP2001514978A JP2001514978A JP2003513012A5 JP 2003513012 A5 JP2003513012 A5 JP 2003513012A5 JP 2001514978 A JP2001514978 A JP 2001514978A JP 2001514978 A JP2001514978 A JP 2001514978A JP 2003513012 A5 JP2003513012 A5 JP 2003513012A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- nhl
- bone marrow
- lymphoma
- stated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 24
- 210000001185 bone marrow Anatomy 0.000 description 14
- 230000003902 lesion Effects 0.000 description 12
- 239000008194 pharmaceutical composition Substances 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 208000003950 B-cell lymphoma Diseases 0.000 description 7
- 229960004641 rituximab Drugs 0.000 description 7
- 239000012634 fragment Substances 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000003325 follicular Effects 0.000 description 3
- 238000011363 radioimmunotherapy Methods 0.000 description 3
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 206010052178 Lymphocytic lymphoma Diseases 0.000 description 2
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 201000003444 follicular lymphoma Diseases 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 238000004980 dosimetry Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- NYNAFINLHQEHKU-UHFFFAOYSA-N methyl 1-(4-{[(2,4-diaminopteridin-6-yl)methyl]amino}benzoyl)piperidine-4-carboxylate Chemical compound C1CC(C(=O)OC)CCN1C(=O)C(C=C1)=CC=C1NCC1=CN=C(N=C(N)N=C2N)C2=N1 NYNAFINLHQEHKU-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14828799P | 1999-08-11 | 1999-08-11 | |
| US60/148,287 | 1999-08-11 | ||
| PCT/US2000/040459 WO2001010462A1 (en) | 1999-08-11 | 2000-07-25 | Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003513012A JP2003513012A (ja) | 2003-04-08 |
| JP2003513012A5 true JP2003513012A5 (https=) | 2007-06-28 |
Family
ID=22525101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001514978A Pending JP2003513012A (ja) | 1999-08-11 | 2000-07-25 | 抗ｃｄ２０抗体による骨髄病変を伴う非ホジキンリンパ腫を有する患者の治療 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1207906A4 (https=) |
| JP (1) | JP2003513012A (https=) |
| CN (2) | CN100389825C (https=) |
| AU (1) | AU784971B2 (https=) |
| CA (1) | CA2378646A1 (https=) |
| MX (1) | MXPA02001398A (https=) |
| MY (1) | MY136635A (https=) |
| NO (1) | NO20020639L (https=) |
| TW (1) | TWI279233B (https=) |
| WO (1) | WO2001010462A1 (https=) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA01011279A (es) | 1999-05-07 | 2002-07-02 | Genentech Inc | Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b. |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| CN101928344B (zh) | 2002-10-17 | 2014-08-13 | 根马布股份公司 | 抗cd20的人单克隆抗体 |
| EP3263596A1 (en) | 2002-12-16 | 2018-01-03 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| EP2062916A3 (en) | 2003-04-09 | 2009-08-19 | Genentech, Inc. | Therapy of autoimmune disease in a patient with an inadequate response to a TNF-Alpha inhibitor |
| CA2525251C (en) | 2003-05-09 | 2015-10-27 | Duke University | Cd20-specific antibodies and methods employing same |
| PL1631313T3 (pl) | 2003-06-05 | 2015-08-31 | Genentech Inc | Terapia skojarzona zaburzeń z komórek B |
| ES2672640T3 (es) | 2003-11-05 | 2018-06-15 | Roche Glycart Ag | Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| TW201422238A (zh) | 2004-06-04 | 2014-06-16 | Genentech Inc | Ｃｄ２０抗體於治療多發性硬化症之用途及用於該用途之物品 |
| PL1776384T3 (pl) | 2004-08-04 | 2013-10-31 | Mentrik Biotech Llc | WARIANTY REGIONÓW Fc |
| ATE460672T1 (de) | 2005-05-20 | 2010-03-15 | Genentech Inc | Vorbehandlung einer biologischen probe aus einem individuum mit autoimmunkrankheit |
| JP2009502936A (ja) | 2005-07-25 | 2009-01-29 | トルビオン ファーマシューティカルズ， インコーポレイテッド | Ｃｄ２０特異的結合分子の単一投与量 |
| HRP20140338T1 (hr) | 2005-07-25 | 2014-06-20 | Emergent Product Development Seattle, Llc | Smanjenje broja b-stanica upotrebom molekula koje se specifiäśno vežu na cd37 i cd20 |
| MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
| WO2007062090A2 (en) | 2005-11-23 | 2007-05-31 | Genentech, Inc. | Methods and compositions related to b cell assays |
| WO2007146968A2 (en) | 2006-06-12 | 2007-12-21 | Trubion Pharmaceuticals, Inc. | Single-chain multivalent binding proteins with effector function |
| KR20190140090A (ko) | 2007-07-09 | 2019-12-18 | 제넨테크, 인크. | 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지 |
| EP2200631A1 (en) | 2007-10-16 | 2010-06-30 | Zymogenetics, Inc. | Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease |
| EP2077281A1 (en) | 2008-01-02 | 2009-07-08 | Bergen Teknologioverforing AS | Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
| US7914785B2 (en) | 2008-01-02 | 2011-03-29 | Bergen Teknologieverforing As | B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
| EP2365003A1 (en) | 2008-04-11 | 2011-09-14 | Emergent Product Development Seattle, LLC | CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| TW201014605A (en) | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
| RU2535032C2 (ru) * | 2008-12-22 | 2014-12-10 | Милленниум Фармасьютикалз, Инк. | Сочетание ингибиторов аврора киназы и анти-cd 20 антител |
| WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
| JO3434B1 (ar) | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري |
| CN104059955A (zh) | 2009-08-11 | 2014-09-24 | 弗·哈夫曼-拉罗切有限公司 | 在无谷氨酰胺的细胞培养基中的蛋白质生产 |
| TW201129384A (en) | 2010-02-10 | 2011-09-01 | Immunogen Inc | CD20 antibodies and uses thereof |
| CA2788774A1 (en) | 2010-02-19 | 2011-08-25 | Millennium Pharmaceuticals, Inc. | Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate |
| US9814740B2 (en) * | 2010-12-21 | 2017-11-14 | Duke University | Methods and compositions combining immunotherapy with monocyte activation |
| US10017739B2 (en) | 2012-09-06 | 2018-07-10 | Duke University | Methods of expanding and assessing B cells and using expanded B cells to treat disease |
| WO2014153509A1 (en) | 2013-03-22 | 2014-09-25 | Millennium Pharmaceuticals, Inc. | Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase |
| CA2970738A1 (en) * | 2015-01-23 | 2016-07-28 | Immunomedics, Inc. | Combination therapy with anti-cd74 and anti-cd20 antibodies in patients with relapsed and refractory b-cell non-hodgkin's lymphoma |
| AU2016271124C1 (en) | 2015-05-30 | 2020-05-14 | Molecular Templates, Inc. | De-immunized, Shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same |
| MX391086B (es) | 2015-06-24 | 2025-03-21 | Hoffmann La Roche | Anticuerpos anti-receptor de transferrina con afinidad diseñada. |
| EP3352760B1 (en) | 2015-09-21 | 2026-03-11 | Aptevo Research and Development LLC | Cd3 binding polypeptides |
| AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
| NZ741067A (en) | 2015-10-02 | 2023-07-28 | Hoffmann La Roche | Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use |
| SG11201901672RA (en) * | 2016-09-16 | 2019-03-28 | Nordic Nanovector Asa | Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan |
| CN108421048B (zh) * | 2016-09-28 | 2021-04-20 | 首都医科大学附属北京世纪坛医院 | 纳米活性碳靶向药物递送系统、制备方法及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD1367C2 (ro) * | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| US5595721A (en) * | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| CA2340091C (en) * | 1998-08-11 | 2013-02-05 | Idec Pharmaceuticals Corporation | Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody |
| US6451284B1 (en) * | 1999-08-11 | 2002-09-17 | Idec Pharmaceuticals Corporation | Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy |
| US8557244B1 (en) * | 1999-08-11 | 2013-10-15 | Biogen Idec Inc. | Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody |
-
2000
- 2000-07-25 CN CNB008116644A patent/CN100389825C/zh not_active Expired - Lifetime
- 2000-07-25 AU AU76260/00A patent/AU784971B2/en not_active Expired
- 2000-07-25 JP JP2001514978A patent/JP2003513012A/ja active Pending
- 2000-07-25 MX MXPA02001398A patent/MXPA02001398A/es active IP Right Grant
- 2000-07-25 WO PCT/US2000/040459 patent/WO2001010462A1/en not_active Ceased
- 2000-07-25 EP EP00965561A patent/EP1207906A4/en not_active Withdrawn
- 2000-07-25 CN CNA2008100921383A patent/CN101259270A/zh active Pending
- 2000-07-25 CA CA002378646A patent/CA2378646A1/en not_active Abandoned
- 2000-08-03 MY MYPI20003551A patent/MY136635A/en unknown
- 2000-08-10 TW TW089116114A patent/TWI279233B/zh not_active IP Right Cessation
-
2002
- 2002-02-08 NO NO20020639A patent/NO20020639L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003513012A5 (https=) | ||
| JP2003513012A (ja) | 抗ｃｄ２０抗体による骨髄病変を伴う非ホジキンリンパ腫を有する患者の治療 | |
| JP2004512262A5 (https=) | ||
| Olsson et al. | Early oral contraceptive use and breast cancer among premenopausal women: final report from a study in southern Sweden | |
| JP2002529429A (ja) | Ｂｍｔまたはｐｂｓｃ移植を受ける患者のキメラ化抗ｃｄ２０抗体による治療。 | |
| CA2378574A1 (en) | Treatment of intermediate-and high-grade non-hodgkins lymphoma with anti-cd20 antibody | |
| CA2378584A1 (en) | New clinical parameters for determining hematologic toxicity prior to radioimmunotherapy | |
| JP2005515182A (ja) | 抗腫瘍剤により誘導される心臓毒性を処置するためのデクスラゾキサン | |
| Hart et al. | One‐day vath (vinblastine, adriamycin, thiotepa, and halotestin) therapy for advanced breast cancer refractory to chemotherapy | |
| Raut et al. | Unusual gingival presentation of post-transplantation lymphoproliferative disorder: a case report and review of the literature | |
| Borghaei et al. | Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin) | |
| CN101678101A (zh) | 可用于诊断和治疗b细胞慢性淋巴细胞白血病的能够在肿瘤细胞中诱导凋亡的药物组合物 | |
| Mody et al. | CD30-positive cutaneous T-cell lymphoma and response to Brentuximab Vedotin: 2 illustrative cases | |
| Lo et al. | Can the hormonal receptor status of primary breast cancer be altered by neoadjuvant chemotherapy? | |
| Hiddemann et al. | Mantle cell lymphoma: therapeutic strategies are different from CLL | |
| Butty et al. | Chronic lymphocytic leukemia–associated membranous glomerulopathy: Remission with fludarabine | |
| Morgenroth et al. | Auger electron emitter against multiple myeloma—targeted endo-radio-therapy with 125I-labeled thymidine analogue 5-iodo-4′-thio-2′-deoxyuridine | |
| Furman et al. | Testicular relapse in children with acute nonlymphoblastic leukemia | |
| MX2007000327A (es) | Tratamiento del linfoma de celulas b. | |
| Kolarić et al. | Combination of idarubicin and cyclophosphamide administered orally in untreated postmenopausal breast cancer patients: a phase II study | |
| Pan et al. | CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas | |
| TWI280137B (en) | Treatment of intermediate-and high-grade non-Hodgkins lymphoma with anti-CD20 antibody | |
| EP4618995A1 (en) | Therapeutic combinations of capivasertib and venetoclax | |
| Rathore et al. | The chronic leukemias: current and novel therapeutic approaches | |
| Lipton et al. | Intensive remission induction therapy for chronic myeloid leukemia in blast phase with a goal of post‐remission bone marrow transplant→—a pilot study |